The European Commission has approved Merck’s Erbitux BRAF V600E mCRC combination regimen cetuximab plus encorafenib and FOLFOX as first-line therapy for metastatic colorectal cancer with the BRAF V600E mutation, based on Phase 3 BREAKWATER data showing a 51% reduction in risk of death versus standard chemotherapy.
Merck has secured an FDA Breakthrough Therapy designation for enpatoran, an investigational oral TLR7/8 inhibitor aiming to address the high unmet need in lupus patients suffering from active skin manifestations.
Merck KGaA has entered into a definitive agreement to acquire Bio-Techne for US$73 per share in cash, representing an enterprise value of US$11.3 billion to strengthen its global leadership in high-growth life sciences markets.
Merck delivers a robust Q1 2026 performance with €5.1 billion in sales. Driven by its Life Science and Electronics sectors, the company has officially upgraded its full-year outlook.
Merck has successfully launched a new, energy-efficient high-performance computer in Munich to accelerate research across its three sectors. Developed with Lenovo ThinkSystem servers featuring Neptune liquid cooling and hosted in an Equinix AI-ready data center, the hybrid cloud system enhances drug discovery, product development, and materials science while supporting Merck’s sustainability goals.
Merck delivered solid Q3 2025 results, achieving 5.2% organic growth that successfully offset significant currency headwinds. This resilience was seen across all three business sectors, driven by strong demand for Process Solutions in Life Science, the new Rare Diseases franchise in Healthcare, and AI-driven demand for Semiconductor Solutions.
